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Immunoglobulin-E-mediated reactivity to self antigens: a
controversial issue
Abstract
Immunoglobulin E (IgE) reactivity to self antigens is well established in vitro by ELISA, inhibition
ELISA, Western blot analyses and T cell proliferation experiments. In vivo, IgE-binding self antigens
are able to elicit strong type I reactions in sensitized individuals and, in the case of human manganese
superoxide dismutase, to elicit eczematous reactions on healthy skin areas of patients suffering from
atopic eczema. The reactions against self antigens sharing structural homology with environmental
allergens can be plausibly explained by molecular mimicry between common B cell epitopes. For the
second class of IgE-binding self antigens without sequence homology to known allergens, it is still
unclear if the structures are able to induce a B cell switch to IgE production, or if the reactivity is due to
sequence similarity shared with not yet detected environmental allergens. However, in all cases,
cross-reactivity is never complete, indicating either a lower affinity of IgE antibodies to self allergens
than to the homologous environmental allergens or the presence of additional B cell epitopes on the
surface of the environmental allergens, or both. Increasing evidence shows that self allergens could play
a decisive role in the exacerbation of long-lasting atopic diseases. However, the only observation
supporting a clinical role of IgE-mediated autoreactivity is confined to the fact that IgE levels against
self antigens correlate with disease severity. 2007 S. Karger AG, Basel
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 exacerbation of long-lasting atopic diseases. However, the 
only observation supporting a clinical role of IgE-mediated 
autoreactivity is confined to the fact that IgE levels against 
self antigens correlate with disease severity.
 Copyright © 2007 S. Karger AG, Basel
 Introduction
 Historically, the first description of ‘autoreactivity’ 
goes back to the early last century when the sensitivity of 
man to human skin dander was demonstrated  [1, 2] . At 
that time, it was of course not possible to identify the mo-
lecular nature of the endogenous proteins potentially 
serving as targets for immunoglobulin E (IgE) (auto)-an-
tibodies. For this reason, the concept that IgE-mediated 
autoreactivity might play a role in the pathogenesis of al-
lergic diseases was not followed further, until progress in 
modern molecular biology methods allowed to identify, 
clone and produce IgE-binding self antigens which are 
expressed in a variety of human tissues and cell types  [3, 
4] . To date, a long list of IgE-binding self antigens has 
been described, and those best investigated are reported 
in  table 1 . Although IgE-mediated reactivity to self anti-
gens has been clearly shown in vitro and in vivo  [3, 5–12] , 
it is still unclear if and how immune recognition of IgE-
reactive autoantigens can contribute to the pathogenesis 
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 Abstract
 Immunoglobulin E (IgE) reactivity to self antigens is well es-
tablished in vitro by ELISA, inhibition ELISA, Western blot 
analyses and T cell proliferation experiments. In vivo, IgE-
binding self antigens are able to elicit strong type I reactions 
in sensitized individuals and, in the case of human manga-
nese superoxide dismutase, to elicit eczematous reactions 
on healthy skin areas of patients suffering from atopic ec-
zema. The reactions against self antigens sharing structural 
homology with environmental allergens can be plausibly 
explained by molecular mimicry between common B cell 
epitopes. For the second class of IgE-binding self antigens 
without sequence homology to known allergens, it is still 
unclear if the structures are able to induce a B cell switch to 
IgE production, or if the reactivity is due to sequence similar-
ity shared with not yet detected environmental allergens. 
However, in all cases, cross-reactivity is never complete, in-
dicating either a lower affinity of IgE antibodies to self aller-
gens than to the homologous environmental allergens or 
the presence of additional B cell epitopes on the surface of 
the environmental allergens, or both. Increasing evidence 
shows that self allergens could play a decisive role in the 
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of allergic inflammation. However, there is increasing 
evidence deriving from structural work comparing pairs 
of homologous environmental and self antigens  [11–14] 
and from cellular work  [15–17] indicating that the ob-
served phenomenon of autoreactivity to self antigens is 
due to molecular mimicry between shared B cell epitopes 
situated at the end of the sensitization process.
 Allergenicity, Autoreactivity and Autoimmunity
 In order to understand complex phenomena like
the ability of human manganese superoxide dismutase 
(MnSOD) to elicit eczema formation after application to 
the skin of MnSOD-sensitized individuals  [9, 18] , it is im-
portant to precisely define the terms allergenicity, auto-
reactivity and autoimmunity.
 The allergenicity of a protein reflects two properties: (1) 
the potential to induce allergen-specific IgE antibodies 
through induction of B cell isotype switches (sensitiza-
tion), and (2) the potential to induce symptoms by cross-
linking of membrane-bound allergen-specific IgE on ef-
fector cells, normally reflected by a positive skin test in 
sensitized individuals. These two intrinsic properties of an 
allergen are not necessarily linked. In fact, sensitization to 
Api g 1, the major celery allergen which is structurally re-
lated to the major birch pollen allergen Bet v 1  [19] , is fre-
quent in Central Europe where birch allergy is common, 
but not in Southern Europe where birch is absent  [20] . Al-
though celery allergy is quite common in the Mediterra-
nean area, sensitization in this geographic area occurs 
through various celery allergens but not through Api g 1 
 [20] , indicating a low allergenic potential of Api g 1, if any. 
Cellular work involving T cell lines and T cell clones dem-
onstrated that humoral as well as cellular reactivity to Api 
g 1 is predominantly based on cross-reactivity with the 
major birch pollen allergen Bet v 1  [21, 22] . Finally, the re-
cently solved crystal structure of Api g 1  [23] allows a deep 
analysis of the cross-reactivity between Api g 1 and Bet
v 1 confirming, at structural level, the predominant role of 
cross-reactivity in sensitization to Api g 1, earlier shown by 
mutational epitope analysis  [24] . Together, these data 
clearly demonstrate that allergens like Api g 1 might elicit 
symptoms by cross-linking the bound IgE on the surface 
of mast cells, although they are not able to induce the se-
cretion of allergen-specific IgE antibodies by B cells.
 Allergenicity related to the ability of a protein to in-
duce symptoms based on cross-reactivity is a quite com-
mon phenomenon in pollen-food syndromes as indicated 
by the consumption of apples which rarely, if ever, induc-
es IgE antibodies but may elicit allergic symptoms in pa-
tients with peach allergy or birch pollinosis  [16] .
 Autoreactivity can be defined as an antigen-antibody 
response to self antigens and is not necessarily linked to 
an autoimmune response. Like IgE-mediated responses 
to pollen-food allergens, autoreactivity can occur be-
tween self antigens and structurally related environmen-
tal antigens as a result of molecular mimicry which will 
be discussed in detail below. In contrast, autoimmunity 
results from the production of autoantibodies raised 
against self antigens  [25, 26] .
 B cell cross-reactivity, which is important for mast cell 
triggering, is straightforward, as it concerns only B cell 
epitopes. In contrast to T cell cross-reactivity which in-
volves linear epitopes, B cell cross-reactivity is exquisite-
ly dependent on conformational features  [27] . Unfortu-
nately, misconceptions regarding the term ‘epitope’ are 
widespread in the literature, probably generated through 
different experimental setups, as pointed out earlier by 
Laver et al.  [28] . The only method to determine the com-
plete structure of a B cell epitope is the preparation of a 
complex of a monoclonal antibody Fab fragment with its 
antigen, cocrystallization of the complex and determina-
tion of its structure resolving those determinants recog-
nized by the complementary determining regions of the 
antibody on the native protein. All Fab/antigen complex-
es solved so far by X-ray crystallography reveal discon-
tinuous B cell epitopes, including a recent study on bind-
ing and structural characterization of cross-reactive phy-
logenetically conserved  Plasmodium proteins  [29] . This 
study also shows that the binding affinity of the mono-
clonal antibody raised against the apical membrane anti-
gen 1 from  Plasmodium vivax to the homologous cross-
reacting apical membrane antigen 1 antigen from  Plas-
modium falciparum is about 100-fold weaker compared 
with binding to the cognate antigen. This difference in 
affinity can be traced back to differences in contacts be-
tween the antibody and the homologous antigens.
 Unfortunately, the common methods used to investi-
gate cross-reactivity such as ELISA, Western blot analy-
ses and inhibition experiments are not sensitive enough 
to reveal differences in antigen-antibody affinity which 
might have profound physiological consequences.
 IgE-Binding Self Antigens
 The first reported autoantigen able to bind serum IgE 
from allergic individuals was human profilin  [5] , a pro-
tein structurally related to the birch pollen allergen Bet
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v 2. It was demonstrated that profilins constitute a wide 
family of pan-allergens  [30] ; however, human profilin 
was not able to induce immediate type I reactions in 
skin test challenges of allergic individuals sensitized to 
Bet v 2  [4] . A plausible explanation for this observation 
could be that the affinity of the cross-reactive IgE anti-
bodies raised against Bet v 2 is not high enough for hu-
man profilin to induce mast cell degranulation. In con-
trast, many other self antigens like MnSOD  [6] , ribo-
somal P 2  protein  [7] , cyclophilin (CyP)  [8, 11] and 
thioredoxin  [10, 12] , which all show a strong structural 
similarity to environmental allergens, as well as self an-
tigens without structural similarity to environmental 
allergens like cytokeratin type II or BCL7B  [3] clearly 
elicit positive results in skin test challenges ( table 1 ). 
However, the number of IgE-binding self antigens is 
certainly much larger than those described so far. High 
throughput screening of a human lung cDNA library 
displayed on phage surface  [31, 32] revealed more than 
150 partial and complete cDNA sequences potentially 
encoding IgE-binding proteins. Although not yet ana-
lyzed in detail, some of the cDNA sequences, like those 
encoding   -tubulin  [33] or ribosomal L 3  protein  [34] , 
show a high degree of sequence identity and cross-reac-
tivity to environmental allergens [Zeller et al., unpub-
lished results]. In these cases, it makes sense to assume 
that IgE autoreactivity can be traced back to common 
structural features shared between environmental and 
self antigens (see below). However, structural similarity 
of the environmental allergen should probably not be 
too similar to the corresponding human antigen as 
strongly autoreactive B cells can be expected to be de-
leted from the repertoire  [16, 35] . Although the reper-
toire of allergenic structures is supposed to be limited 
 [36] , it is unfortunately far from complete. This unsatis-
factory situation does not allow a bioinformatic evalua-
tion of cDNA sequences without homology to known 
environmental allergens for their cross-reactive poten-
tial.
 Table 1. Self antigens confirmed as IgE-binding molecules in vitro and in skin test challenges in vivo




 Function  GenBank




 SART-1 (Hom s 1)  73  cell cycle arrest and apoptosis  AB006198  48, 49 
  -NAC (Hom s 2)  33  intracellular localization of nascent
 polypeptides, activator of transcription 
 AJ278883  3, 50 
 BCL7B (Hom s 3)  20  oncogene  X89985  3 
 Hom s 4  Cyp c 1
 Phl p 7 
 54  Y17711  3, 51 
 Cytokeratin type II (Hom s 5)  43  component of the cytoskeleton  3 
 Profilin  Bet v 2 15  actin polymerization  NM_005022  1pfl  5 
 Ribosomal P 2  Asp f 8  13  part of the 60 S ribosome  AJ224333  7 
 MnSOD  Asp f 6  26  superoxide dismutase   Y00472  1ABM  13 
 Mala s 11 
 Hev b 10 
 Cyclophilin B  Asp f 27  23  peptidyl-prolyl  cis-trans isomerase  NM_000942  2CPL  11 
 Asp f 11 
 Mala s 6 
 Thioredoxin  Mala s 13  12  oxidoreductase  X77584
 NM_003329 
 1ERU  12 
 Tri a 25 
 Zea m 25 
 ZmTRX h 2 
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 The Structural Basis of Cross-Reactivity
 Recently, the 3D structures of many allergens have 
been solved  [37] , allowing detailed comparisons between 
homologous structures. With respect to cross-reactivity 
to self antigens, the most interesting structures are those 
allowing a pair-wise comparison between the environ-
mental and the corresponding human protein. MnSOD 
 [6, 9, 13] , CyP  [8, 11] and thioredoxin  [12] belong to this 
class, and the most exciting example is, perhaps, CyP. 
CyPs constitute a family of cytosolic proteins which play 
a pivotal role in protein folding through enzymatic ca-
talysis of the peptidyl-prolyl  cis-trans isomerization reac-
tion  [38] . The primary structure of this important en-
zyme is highly conserved among phylogenetically distant 
species, indicating the involvement of CyP in basic cel-
lular functions  [39] . CyP was first reported to be an al-
lergen (Psi c 2) isolated from the basidiomycete  Psilocybe 
cubensis  [40] , and later, from phage surface-displayed li-
braries of  Aspergillus fumigatus (Asp f 11, Asp f 27) [11, 
14] ,  Candida albicans  [8] and  Malassezia sympodialis 
(Mala s 6) [8, 41] . CyP as allergen is not limited to the fun-
gal kingdom but is also described as an allergen from var-
ious pollens  [42] and foods  [43] .
 The crystal structure of  M. symodialis CyP (Mala s 6) 
has now been solved at 1.50 Å resolution  [11] . Together 
with the solved structures of the homologous human 
CyPs, the new structure allows an exact comparison of 
the spatial orientation of conserved amino acids between 
self/non-self antigens. On the structural level, Mala s 6 
and human CyPs superpose well with a root mean square 
deviation of 1.05 Å for all C  atoms of the protein back-
bone. Because Mala s 6 and human CyPs show cross-re-
activity in Western blot analyses  [8] , ELISA and skin 
challenges  [11] , they must share common IgE-binding ep-
itopes. Obviously, only those residues that are identical in 
pairs of allergens and at least partly exposed to the solvent 
can contribute to the binding of cross-reactive IgE anti-
bodies in native proteins. Thus, solvent-accessible resi-
dues conserved in both proteins are potentially involved 
in IgE-mediated cross-reactivity. Although the sequence 
identity between Mala s 6, human CyP A, CyP B and CyP 
C reach values of 71, 63 and 60% at primary structure 
level, respectively, only a very limited number of identical 
amino acids are exposed to the solvent in correctly folded 
protein pairs ( fig. 1 ). The conserved surface-exposed res-
idues are scattered over the whole sequence and are thus 
likely to define the discontinuous structures found in B 
cell epitopes. In the 3D models of the correctly folded 
proteins, these amino acids are clustered over the sur-
faces forming patches covering solvent-accessible surface 
areas which involve 15–22 amino acid residues on differ-
ent surface loops occupying a buried surface compatible 
with the structure of a B cell epitope  [11] .
 Binding of serum IgE to CyPs was determined by
ELISA, and cross-reactivity was demonstrated in com-
petitive inhibition ELISA ( fig. 2 ). However, the observed 
cross-reactivity between fungal and human CyPs, as de-
duced from ELISA inhibition experiments using single 
patients’ sera, ranges between 60 and 30% which is not 
compatible with a complete cross-reactivity. Interesting-
ly, the strongest inhibition was obtained with human CyP 
B which shares the highest number of identical amino 
acids exposed to the solvent with Mala s 6, followed by 
human CyP A and human CyP C, as shown in  figure 1 . 
This might indicate that the cross-reactive epitopes bind 
IgE with a lower affinity depending on the number of 
 Fig. 1. Solvent exposed surfaces of Mala s 6 and the natural human 
isoforms CyP B, CyP A and CyP C. Amino acids which are con-
served in all structures and exposed to the solvent define two pu-
tative IgE-binding epitopes (blue). Asp57 of Mala s 6 which cor-
responds to Asp67 of Cyp B and Asp93 of CyP C is mutated to 
Gly59 in the sequence of CyP A. Lys74 of Mala s 6 corresponds to 
Lys84 in CyP B and Lys76 in CyP A, but is mutated to Val110 in 
CyP C. Further, Val115 of Mala s 6, which corresponds to Val125 
in CyP B is mutated in CyP A and CyP C to Ala117 and Thr151, 
respectively. These mutations (yellow) reduce the size of the puta-
tive cross-reactive B cell epitopes, and therefore, may explain the 
reduced IgE-binding capacity of CyP A and CyP C compared with 
CyP B as seen in inhibition ELISA experiments.
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shared identical amino acids which determine the num-
ber of possible contacts that can be established between 
the allergen and the complementary determining regions 
of the antibodies. However, this approach is not suitable 
to answer the question whether the partial cross-reactiv-
ity observed between Mala s 6 and human CyPs is due to 
differences in affinity or to the lack of additional epitopes 
which could be present in the sensitizing allergen.
 Clinical Relevance of Self Antigens
 Autoreactivity to human proteins has been postulated 
as a pathogenic factor in atopic eczema (AE) based on the 
detection of IgE antibodies directed against various pro-
teins in vivo  [44] . There is no doubt that a variety of hu-
man proteins can induce strong B- and T-cell-mediated 
responses in peripheral blood mononuclear cells of pa-
tients suffering from chronic inflammatory allergic dis-
eases  [6–12] . Intradermal and skin prick tests demon-
strate that self antigens are able to induce IgE cross-link-
ing on the surface of effector cells in vivo. However, a 
positive dermal challenge test does not necessarily cor-
relate with clinical symptoms since up to 40% of the in-
dividuals sensitized to environmental allergens are as-
ymptomatic  [45] . Therefore, skin test challenges with self 
antigens are useful to demonstrate cross-reactivity with 
homologous recombinant allergens or direct sensitiza-
tion to the self antigen, but not for the demonstration of 
the clinical relevance. Although it makes sense to assume 
that self antigen-induced mediator release in vivo could 
have clinical consequences at least for a subset of the pa-
tients, we presently do not have any suitable test to un-
equivocally demonstrate an involvement of self antigens 
in the pathogenesis of allergic diseases.
 Probably the most reliable indication for a role of self 
antigens in the pathogenesis of allergic diseases comes 
from atopy patch tests performed with human MnSOD in 
patients suffering from AE  [9, 46] . This study showed that 
human MnSOD – a stress-inducible enzyme – is able to 
induce eczematous reactions on unaffected skin areas of 
AE patients sensitized to  M. sympodialis. In concordance 
with the presence of MnSOD-specific IgE, the human en-
zyme also elicited positive skin prick test reactions and T 
cell proliferation in all ELISA-positive patients. Interest-
ingly, reactivity against human MnSOD strongly corre-
lated with the severity of the disease, further corroborat-
ing the postulated pathogenic role of self-reactivity in the 
exacerbation of AE  [9] . A further indication that such re-
actions might contribute to the pathogenesis of AE de-
rives from the observation that human MnSOD is upreg-
ulated in eczematous areas as shown by immunohisto-
chemistry, most likely as a consequence of mechanical 
stress due to scratching. Interestingly, also CyPs and thio-
redoxins represent stress-inducible enzymes which are 
upregulated as a consequence of cellular stress. Oxidative 
stress could, through upregulation of nuclear factor-  B 
expression, induce interleukin-4 production  [47] and, as 
a consequence thereof, accentuate Th2 responses to aller-
gens and homologous self antigens.
 Concluding Remarks
 Evidence is increasing that self antigens are a contrib-
uting factor to the exacerbation of long-standing, inflam-
matory atopic diseases. Structural data provide informa-
tion allowing a rational explanation of cross-reactivity 
 Fig. 2. Inhibition of IgE binding to solid phase-coated Mala s 6, 
with Mala s 6, homologous human CyPs and BSA as a negative 
control. Serum of a Mala s 6 sensitized patient was preincubated 
with increasing concentrations of Mala s 6, human CyP B, CyP A, 
CyP C and BSA as negative control. After transfer of the preincu-
bated serum to Mala s 6 coated wells, the residual IgE binding was 
detected by ELISA. Apparently, all human CyPs are able to in-
hibit the binding of IgE to Mala s 6, indicating that Mala s 6 and 
the homologous human proteins share common cross-reactive 
IgE-binding epitopes. The reduced capacity to inhibit the IgE 
binding to Mala s 6 of CyP A and CyP C compared with CyP B 
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between environmental allergens and structurally relat-
ed self antigens. There is no doubt that structural features 
which are shared between self antigens such as MnSOD, 
CyPs and thioredoxin and homologous environmental 
(pan)-allergens are responsible for the common IgE-
binding capacity observed in Western blot analyses, ELI-
SA and competitive inhibition ELISA, as well as for their 
ability to elicit positive skin or atopy patch tests. Cross-
reactivity between these molecules is never complete, in-
dicating that either environmental allergens elicit, beside 
cross-reactive, additional IgE-binding epitopes, or that 
the B cell epitopes displayed on the surface of self anti-
gens have a reduced IgE-binding affinity. Either reason 
or their combination could be sufficient to explain the 
reduced IgE-binding capability of self antigens compared 
with their homologous environmental allergens. In con-
trast to the cross-reactivity between human and homolo-
gous environmental allergens which was studied in deep 
detail, not much is known about the autoreactivity of self 
antigens without sequence homology to environmental 
allergens. It is still not clear if they are able to directly in-
duce a B cell switch towards IgE production, or if the ob-
served IgE-binding capability is due to cross-reactivity 
with not yet identified environmental allergen structures. 
However, clear evidences showing that autoreactivity 
could be a pathogenic factor for severe chronic allergic 
diseases are still lacking, and the only indication that this 
could be the case is limited to the observation that the 
levels of IgE autoantibodies in AE patients correlate to the 
severity of the disease.
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